Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine
Our guests are Ofer Sharon, CEO of OncoHost; Matthew Lakelin, co-founder, TrakCel; Pierre Belichard, CEO…
February 3, 2023 - 4 minutes
Cancer: Keep up to Date with the Latest in Oncology
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
Show More
Editor's Picks for Cancer
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Immuno-Oncology: From Science Fiction to the Mainstream
- ADC Approval Buoys Spirits in Cancer Treatment Space
- Do Natural Killer Cells Hold the Key to Treating Blood Cancers?
- Meet 20 European Immuno-Oncology Companies that are Fighting Cancer
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest Cancer Articles
Genoscience Pharma receives orphan drug designation for hepatocellular carcinoma drug
Genoscience Pharma has announced that its lead candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor,…
February 3, 2023 - 3 minutes
How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic
By Joe Oakley, MD, medical director of biomarker development, Paige Just as much of medicine…
February 2, 2023 - 8 minutes
Orbit Discovery and Endevica Bio to develop cachexia therapeutics
Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. …
February 2, 2023 - 3 minutes
Almost 20% of cancer trials have recruited only one patient
Phesi Inc., a global provider of clinical development data analytics, has published an analysis of…
February 2, 2023 - 3 minutes
Recurv Pharma receives funding for cancer therapy development
Recurv Pharma Inc. is receiving up to $24 million in funding from TVM Capital Life…
February 2, 2023 - 2 minutes
Foundation for the National Institutes of Health: partnering to tackle cancer
The Foundation for the National Institutes of Health (FNIH) takes on cancer through public-private research…
February 1, 2023 - 8 minutes
The future of cancer treatment: Exploiting cancer’s key vulnerabilities
By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck…
February 1, 2023 - 4 minutes
Expanding the world of biomarkers with proteogenomics
By Michael Pisano, executive vice president, proteomics, Discovery Life Sciences In oncology, characterizing genetic markers…
February 1, 2023 - 7 minutes
How can patients have access to the latest science?
Innovation in cancer research is happening at an accelerated rate, but the current healthcare system…
February 1, 2023 - 6 minutes
Cancer: what are the barriers to research?
Everyone imagines a world without cancer, but getting there is difficult. With World Cancer Day…
February 1, 2023 - 6 minutes
Next-generation small molecules hold promise for immunotherapy
By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1…
February 1, 2023 - 3 minutes
